Clinical Trials
2 trialsNCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT00718770 2014-01-17
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
University of Colorado, Denver
Phase EARLY_PHASE1 Completed